We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
Read MoreHide Full Article
Sorrento Therapeutics (SRNE - Free Report) moved up 6.21% in August, during market hours, after the drugmaker announced positive results from its drug candidate, Abivertinib. The drug is being evaluated for treating advanced non-small cell lung cancer (NSCLC) patients resistant to first-line EGFR kinase inhibitor therapies.
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor being evaluated by Sorrento in a pivotal late-stage study in China.
The company reported an overall response rate (ORR) of 56.5% (118/209) in 209 evaluable NSCLC patients being treated with abivertinib. The candidate also exhibited a complete response rate (CRR) of 5.3% (11/209) and median overall survival (OS) of 28.2 months in the aforementioned patient population.
Sorrento is ending the study of abivertinib, and based on this data, it will be preparing to apply for a pre-new drug application (NDA) meeting with the FDA. The company also intends to submit documentation for the approval of abivertinib as a treatment for NSCLC to regulatory agencies of other countries as well.
Sorrento shares have declined 57% in the year-to-date period compared with the industry’s decline of 21.6%.
Image Source: Zacks Investment Research
The targeted market represents a significant market opportunity.
Sorrento is a clinical and commercial stage biopharma company focused on developing next generation treatments for infectious diseases, pain and cancer. The company added abivertinib to its portfolio, as a part of its ACEA Therapeutics acquisition, completed in June 2021. The acquisition significantly strengthened Sorrento’s oncology franchise.
Sorrentto also received an investigational new drug (“IND”) application clearance from the FDA, in May 2022, for evaluating abivertinib in patients with metastatic castrate-resistant prostate cancer (mCRPC) in the United States in a phase II MAVERICK study.
In March 2022, the company received FDA clearance for the commencement of phase II/III study for abivertinib in the treatment of hospitalized patients with severe pneumonia due to COVID-19. The late-stage study will be conducted at multiple sites in the United States, Brazil and Mexico.
Sorrento’s abivertinib for treating NSCLC, if and when approved, will face stiff competition from AstraZeneca’s (AZN - Free Report) already approved lung-cancer drug Tagrisso (Osimertinib).
AZN’s Tagrisso has already been approved in the United States, European Union, Japan and China as a second-line treatment option for patients with EGFR mutation-positive NSCLC.
Inozyme’s loss per share estimates for 2022 have narrowed from $2.08 to $1.84 in the past 30 days. The same for 2023 has narrowed from $1.95 to $1.82 in the same time frame.
Earnings of Inozyme missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average earnings surprise for INZY is 6.65%.
Pliant’s loss per share estimates for 2022 have improved from $3.28 to $3.01 in the past 30 days. The same for 2023 has narrowed from $3.68 to $3.29 in the same time frame.
Earnings of Pliant beat estimates in two of the trailing four quarters, were in line in one and missed the same on the remaining occasion. The average earnings surprise for PLRX is 0.90%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
Sorrento Therapeutics (SRNE - Free Report) moved up 6.21% in August, during market hours, after the drugmaker announced positive results from its drug candidate, Abivertinib. The drug is being evaluated for treating advanced non-small cell lung cancer (NSCLC) patients resistant to first-line EGFR kinase inhibitor therapies.
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor being evaluated by Sorrento in a pivotal late-stage study in China.
The company reported an overall response rate (ORR) of 56.5% (118/209) in 209 evaluable NSCLC patients being treated with abivertinib. The candidate also exhibited a complete response rate (CRR) of 5.3% (11/209) and median overall survival (OS) of 28.2 months in the aforementioned patient population.
Sorrento is ending the study of abivertinib, and based on this data, it will be preparing to apply for a pre-new drug application (NDA) meeting with the FDA. The company also intends to submit documentation for the approval of abivertinib as a treatment for NSCLC to regulatory agencies of other countries as well.
Sorrento shares have declined 57% in the year-to-date period compared with the industry’s decline of 21.6%.
Image Source: Zacks Investment Research
The targeted market represents a significant market opportunity.
Sorrento is a clinical and commercial stage biopharma company focused on developing next generation treatments for infectious diseases, pain and cancer. The company added abivertinib to its portfolio, as a part of its ACEA Therapeutics acquisition, completed in June 2021. The acquisition significantly strengthened Sorrento’s oncology franchise.
Sorrentto also received an investigational new drug (“IND”) application clearance from the FDA, in May 2022, for evaluating abivertinib in patients with metastatic castrate-resistant prostate cancer (mCRPC) in the United States in a phase II MAVERICK study.
In March 2022, the company received FDA clearance for the commencement of phase II/III study for abivertinib in the treatment of hospitalized patients with severe pneumonia due to COVID-19. The late-stage study will be conducted at multiple sites in the United States, Brazil and Mexico.
Sorrento’s abivertinib for treating NSCLC, if and when approved, will face stiff competition from AstraZeneca’s (AZN - Free Report) already approved lung-cancer drug Tagrisso (Osimertinib).
AZN’s Tagrisso has already been approved in the United States, European Union, Japan and China as a second-line treatment option for patients with EGFR mutation-positive NSCLC.
Sorrento Therapeutics, Inc. Price
Sorrento Therapeutics, Inc. price | Sorrento Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Currently, SRNE has a Zacks Rank #3 (Hold).
Some better stocks in the same sector are Inozyme Pharma (INZY - Free Report) and Pliant Therapeutics (PLRX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Inozyme’s loss per share estimates for 2022 have narrowed from $2.08 to $1.84 in the past 30 days. The same for 2023 has narrowed from $1.95 to $1.82 in the same time frame.
Earnings of Inozyme missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average earnings surprise for INZY is 6.65%.
Pliant’s loss per share estimates for 2022 have improved from $3.28 to $3.01 in the past 30 days. The same for 2023 has narrowed from $3.68 to $3.29 in the same time frame.
Earnings of Pliant beat estimates in two of the trailing four quarters, were in line in one and missed the same on the remaining occasion. The average earnings surprise for PLRX is 0.90%.